Lv3
300 积分 2025-10-14 加入
Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease
1个月前
已完结
[Chinese guideline on the diagnosis and treatment of thyroid-associated ophthalmopathy (2022)]
1个月前
已完结
A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease
1个月前
已完结
Extranodal natural killer/T‐cell lymphoma: From fatal to curable
2个月前
已完结
Retinal structure and microcirculation alterations in dysthyroid optic neuropathy: A comprehensive OCTA study
2个月前
已完结
Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease
2个月前
已完结
Extraocular muscle volume reduction in a patient treated with two courses of teprotumumab for thyroid eye disease
2个月前
已完结
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients
3个月前
已完结
Intraorbital rituximab to treat orbital inflammation in a patient with active neoplasia
4个月前
已关闭
皖公网安备34019202002308
